Long-term use of albuterol side effects
Pro Research Analysisby 
Searched over 200M research papers
Long-Term Use of Albuterol: Side Effects and Safety
Introduction to Albuterol and Its Usage
Albuterol is a widely used beta2-adrenergic agonist that helps relax airway smooth muscles, making it a common treatment for asthma and other respiratory conditions. It is available in various forms, including metered-dose inhalers (MDIs), oral tablets, and nebulizer solutions . While effective in managing acute bronchospasm, concerns have been raised about the long-term safety of regular albuterol use.
General Safety of Long-Term Albuterol Use
Adverse Events and Tolerability
Several studies have investigated the safety profile of long-term albuterol use. A study comparing levalbuterol and racemic albuterol over 52 weeks found that both were well tolerated, with similar rates of adverse events (72.0% for levalbuterol and 76.8% for racemic albuterol) . Serious adverse events and discontinuations due to adverse events were low (<15%) and comparable between the two groups . Another study comparing HFA albuterol to CFC albuterol over one year also reported similar safety profiles, with no serious adverse events attributed to the study drugs .
Specific Side Effects
Long-term albuterol use can lead to several dose-related side effects. These include metabolic effects such as decreased plasma potassium, phosphate, calcium, and magnesium levels, and increased plasma glucose, insulin, renin, lactate, and ketone levels . Cardiovascular effects like peripheral vasodilation, decreased systemic and pulmonary vascular resistance, increased pulse pressure, and tachycardia have also been noted . Additionally, skeletal muscle tremors are a common side effect, particularly with parenteral administration .
Impact on Lung Function and Efficacy
Pulmonary Parameters
Long-term studies have shown that regular use of albuterol does not lead to deterioration in lung function. In a year-long study, the mean percentage of predicted FEV1 improved after dosing and remained stable for both levalbuterol and racemic albuterol groups . Similarly, another study found that predose FEV1 increased slightly over 12 months for both HFA and CFC albuterol, although bronchodilator efficacy decreased over time .
Efficacy in Special Populations
In patients with late-onset Pompe disease, extended-release albuterol showed potential benefits as an adjunctive therapy. The study reported improvements in forced vital capacity, forced expiratory volume, and performance in the six-minute walk test, with no serious adverse events related to albuterol . This suggests that albuterol can be beneficial in specific patient populations when used alongside other treatments.
Conclusion
Overall, long-term use of albuterol appears to be well tolerated with a manageable safety profile. While some dose-related side effects are noted, they are generally mild and less prominent with aerosol administration. Regular monitoring and appropriate dosing can help mitigate these risks, making albuterol a viable long-term treatment option for managing chronic respiratory conditions.
Sources and full results
Most relevant research papers on this topic
Long-term safety study of levalbuterol administered via metered-dose inhaler in patients with asthma.
Regular use of levalbuterol HFA MDI or racemic albuterol HFA MDI for up to 52 weeks was well tolerated and no deterioration of lung function was detected during the study period.
DOI